Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNER	≀SHIP

	OMB APPRO	OVAL							
	OMB Number:	3235-0287							
	Estimated average burden hours per response: 0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Harris Erik					Ultragenyx Pharmaceutical Inc. [ RARE ]									(Chec	k all app Direc	licable) tor	ng Person(s) to Is: 10% Ow Other (s		vner	
(Last)	(Fir	,	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/19/2021								X	belov	Officer (give title below) Other (below) Other (below)  VP & Chief Commercial Officer (below)				
(Street) NOVATO			4949 Zip)		4. If <i>F</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)									Form Form	ual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Table	I - No	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benef	icially	/ Own	ed				
D. This or occurry (mean of				Date	Date (Month/Day/Year) if		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)		4 and Secui Bene		cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	Amount	(A) (D)	or Pri	ce	Transa	saction(s) r. 3 and 4)							
Common	ommon Stock 06/1				021		S <sup>(1)</sup>		437	D	\$9	94.63	20	6,280		D				
Common	Stock			06/21/2	2021				S <sup>(2)</sup>		572	D	\$9	\$94.96 25,708 <sup>(3)</sup>				D		
		Tal									osed of, osonvertib				Owne	d				
1. Title of Derivative Security (Instr. 3)	titive   Conversion   Date   Execution Date,   Transactio   Code (Inst							6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In:	Price of rivative curity str. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Dire or li (I) (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amou or Numb of Share	er						

## **Explanation of Responses:**

- 1. Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- 2. The sales reported on the transaction date of June 21, 2021 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934,
- 3. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

## Remarks:

/s/ Karah Parschauer, attorney-06/23/2021 in-fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.